OJU1.SG: Summary for Oramed Pharmaceuticals Inc. Reg - Yahoo Finance

UK Markets closed

Oramed Pharmaceuticals Inc. Reg (OJU1.SG)


Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
7.00-0.28 (-3.87%)
At close: 7:21PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close7.28
Open7.17
Bid0.00 x 200000
Ask0.00 x 200000
Day's range6.95 - 7.22
52-week range5.03 - 9.64
Volume688
Avg. volume177
Market cap
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule
    PR Newswire10 days ago

    Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule

    JERUSALEM, April 20, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a patent titled, "Methods and Compositions for Treating Diabetes: Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes." The patent covers Oramed's invention, a combination therapy including both insulin and a GLP-1 analog in a single oral capsule.

  • Associated Press24 days ago

    Oramed reports 2Q loss

    On a per-share basis, the Jerusalem-based company said it had a loss of 24 cents. The drug maker posted revenue of $611,000 in the period. Oramed shares have risen slightly more than 3 percent since the ...

  • Associated Press24 days ago

    Oramed reports 2Q loss

    On a per-share basis, the Jerusalem-based company said it had a loss of 24 cents. The drug maker posted revenue of $611,000 in the period. Oramed shares have risen slightly more than 3 percent since the ...